We use cookies on our website. Carry on browsing if you’re happy with this or find out more


OX40L monoclonal antibody

Atopic Dermatitis, Phase 2a

Cropped KY1005 Image

KY1005 is a human monoclonal antibody that targets OX40L, a key regulator of the immune system. KY1005 is designed to rebalance the immune system by blocking inappropriate activation and proliferation of ‘pro-inflammatory’ effector T cells and promoting expansion of ‘anti-inflammatory’ regulatory T cells, without broad suppression of the immune system. We believe this mechanism-of-action means KY1005 could be applicable to a range of autoimmune and inflammatory diseases. In our Phase 1 clinical trial in healthy volunteers, KY1005 was able to block T cell-driven skin inflammation while being well tolerated. We are conducting a Phase 2a clinical trial for the treatment of Atopic Dermatitis and expect preliminary results in 2020. We believe the immune-modulating mechanism of KY1005 has broad potential therapeutic application in multiple diseases caused by immune dysregulation.

Kymab's Expanded Access Policy for KY1005 (PDF document)

We discover and develop antibody therapeutics to build a strong portfolio of assets

View our pipeline